Showing results (221-230 of 436) with videos related to
Sort By:
Pageof 44
British Journal of Haematology|July 13, 2010
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patientsQing Yi, Susann Szmania, John Freeman, et al.Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 10, 2002
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.Blood|October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaLijuan Chen, Siqing Wang, Yiming Zhou, et al.Blood|February 13, 2008
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupHeinz Ludwig, Brian G M Durie, Vanessa Bolejack, et al.British Journal of Haematology|December 21, 2002
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIJohn Shaughnessy, Erming Tian, Jeffrey Sawyer, et al.Haematologica|February 8, 2006
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse modelShmuel Yaccoby, Michele J Wezeman, Maurizio Zangari, et al.Cancer|February 14, 2006
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trialPaul G Richardson, Bart Barlogie, James Berenson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myelomaAriel Anguiano, Sascha A Tuchman, Chaitanya Acharya, et al.Seminars in Oncology|July 15, 2005
Southwest Oncology Group: two decades of experience in non-small cell lung cancerAndrew T Turrisi, John Crowley, Kathy Albain, et al.Clinical Lymphoma|July 3, 2003
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survivalMaurizio Zangari, Bart Barlogie, Raymond Thertulien, et al.Pageof 44